Table 1 Baseline Characteristics for Evaluable Patients (N = 67)
Mean age, years (SD) | 69 (± 15) |
|---|---|
Mean body-mass index, kg/m2(SD) | 28.34 (± 6.73) |
Gender (%) | |
Female | 45 (67.2) |
Male | 22 (32.8) |
Race (%) | |
Caucasian | 44 (65.7) |
African American | 18 (26.9) |
Asian | 3 (4.5) |
Other | 2 (3) |
Smoking status (%) | |
Never smoker | 43 (64.2) |
Former smoker | 21 (31.3) |
Current smoker | 3 (4.5) |
Alcohol use (%) | |
No alcohol use | 38 (56.7) |
Infrequent to light use | 21 (31.3) |
Moderate use | 7 (10.4) |
Heavy use | 1 (1.5) |
Cancer Diagnosis (%) | |
Breast cancer | 26 (38.8) |
Hematological malignancies | 22 (32.8) |
Other solid tumors | 19 (28.4) |
Past Medical History (%) | |
Hypertension | 48 (71.6) |
Hyperlipidemia | 27 (40.3) |
Obesity | 26 (38.8) |
Diabetes | 20 (29.9) |
Arrhythmias | 20 (29.9) |
Heart failure (HF) | 17 (25.3) |
Coronary artery disease (CAD) | 14 (20.9) |
Treatment History (%) | |
History of chest radiation | 17 (25.4) |
History of anthracyclines | 15 (22.4) |
History of trastuzumab | 3 (4.5) |
Baseline Cardiovascular Disease (CVD) or CVD Risk Factor (%) | |
At least one risk factor | 65 (97) |
None | 2 (3) |
Classification of Oral Oncolytics (%) | |
Aromatase inhibitors | 25 (36) |
BCR-ABL inhibitors | 11 (16) |
VEGFR inhibitors | 9 (13) |
Immuno-modulators | 7 (10) |
Antiandrogens | 5 (7) |
EGFR inhibitors | 4 (6) |
mTOR inhibitors | 4 (6) |
BTK inhibitors | 3 (4) |
FLT3 inhibitors | 1 (2) |